A large study of pancreatic cancer patients has found that almost 10 percent harbored inherited genetic variations or mutations that may have increased their susceptibility to the disease. At the same time, some of these mutations were associated with more favorable responses to certain chemotherapy agents, according to the scientists from Dana-Farber Cancer Institute.
The findings, published online in Genetics in Medicine today, have prompted Dana-Farber physicians to recommend offering genetic testing to all pancreatic cancer patients at the time of diagnosis, regardless of their age or family history of cancer. Read the story.
